logo

Calithera Biosciences Inc. (CALA)



Trade CALA now with
  Date
  Headline
12/5/2017 8:10:22 AM Calithera Biosciences To Present Updated Clinical Data From Its Lead Product Candidate CB-839
10/5/2017 7:37:55 AM William Blair Initiates Calithera Biosciences Inc. (CALA) At Outperform
9/21/2017 4:07:55 PM Calithera Biosciences Appoints Blake Wise To Board Of Directors
8/7/2017 7:06:01 AM Calithera Biosciences Begins Randomized Phase 2 Combination Trial Of CB-839 In Patients With Renal Cell Carcinoma
6/7/2017 6:47:17 AM Calithera Biosciences Announces FDA Fast Track Designation Granted To CB-839 For Patients With Renal Cell Carcinoma
5/10/2017 7:13:35 AM Bristol-Myers, Calithera Biosciences Expand Collaboration Evaluating Opdivo (nivolumab) Plus CB-839 Into NSCLC
3/28/2017 7:05:58 AM Calithera To Get $12 Mln Milestone Payment From Incyte For Pharmacokinetic, Pharmacodynamic Goals In Phase 1 Study
3/22/2017 7:05:32 AM Calithera Biosciences Prices Public Offering Of 6.83 Mln Shares At $10.25/Shr
3/20/2017 4:05:13 PM Calithera Biosciences Commences Public Offering Of Common Stock